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significantly inhibited tumor growth only in xenograft mod-
els with high (H157) and/or moderate (H460) levels of VEGF 
protein. A combination of erlotinib and bevacizumab par-
tially reversed resistance to erlotinib in H157 xenografts (high 
VEGF level) with increasing intratumoral erlotinib concentra-
tions, but not in H460 (moderate) or A549 (low) xenografts.
Conclusions These results support that combined with 
anti-VEGF therapy could enhance antitumor activity of 
anti-EGFR therapy and/or partially reverse resistance to 
EGFR TKI, by increasing EGFR TKI concentration in spe-
cific tumors that express high levels of VEGF protein.
Keywords Bevacizumab · Drug concentration · 
Erlotinib · Non-small cell lung cancer · VEGF protein
Introduction
Over the past 10 years, targeted therapies, such as small mol-
ecule inhibitors and monoclonal antibodies, have improved 
the treatment of cancers [1]. Lung cancer is the leading cause 
of cancer-related deaths worldwide, and approximately 75 % 
of patients with non-small cell lung cancer (NSCLC, >85 % 
of lung cancer) present with advanced stage disease, which 
is unresectable or metastatic [2, 3]. Thus, the epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors 
(TKIs), erlotinib and gefitinib, and the monoclonal antibody 
against human vascular endothelial growth factor (VEGF), 
bevacizumab, are now components of treatment regimens 
for advanced NSCLC [4]. These targeted drugs received 
approval by the United States Food and Drug Administration 
(FDA) for the treatment of patients with advanced or meta-
static NSCLC, respectively [5–7].
Recently, combination therapy has received much atten-
tion because of its potential to reduce resistance to targeted 
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Purpose Erlotinib, an epidermal growth factor recep-
tor (EGFR) tyrosine kinase inhibitor (TKI), and bevaci-
zumab, an anti-vascular endothelial growth factor (VEGF) 
agent, are promising therapies for advanced non-small cell 
lung cancer (NSCLC). Our study was aimed to determine 
whether there were conditions under which the addition of 
bevacizumab would enhance the antitumor activity of erlo-
tinib against NSCLC tumors in vitro and in vivo.
Methods MTS was for NSCLC cell (PC9, 11–18, H1975, 
H157, H460 and A549) growth assay in vitro. ELISA was 
for VEGF protein assay in cells and tumor tissues. Mouse 
xenograft models were established with H157, H460 and 
A549 with primary resistance to erlotinib and treated with 
erlotinib plus bevacizumab or each agent alone. Erlotinib 
concentrations in tumors were determined by high-perfor-
mance liquid chromatography.
Results Bevacizumab alone did not inhibit NSCLC cell 
growth in vitro. In primarily erlotinib-resistant NSCLC cells, 
the levels of VEGF protein were highest in H157 cell followed 
in order by H460 and A549 cells. In vivo, bevacizumab alone 
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therapies, and/or improve efficacy through the inhibition 
of multiple receptors. At the molecular level, erlotinib 
and bevacizumab target different pathways (EGFR and 
VEGF), which share both parallel and reciprocal down-
stream signaling mechanisms [8, 9]. Phase 1/2 trials dem-
onstrated that median overall survival (OS) was better 
after treatment with erlotinib plus bevacizumab than with 
bevacizumab plus chemotherapy or chemotherapy alone 
in patients with relapsed and refractory non-squamous 
NSCLC [10, 11]. However, phase III trials showed the 
addition of bevacizumab to erlotinib improved progression-
free survival (PFS) but not OS in patients with recurrent, 
advanced or metastatic NSCLC [12, 13]. The reason for the 
lack of additive benefits to erlotinib plus bevacizumab has 
remained speculative.
Since an overactive VEGF pathway independent of 
EGFR plays a role in resistance to EGFR TKI [14], dual 
inhibition of both pathways may prevent resistance through 
VEGF [9]. In addition, several studies have focused on the 
effect of bevacizumab on drug delivery to tumors [15–17]. 
These studies may lead to a breakthrough that explains the 
reason for the lack of synergy in preclinical studies and 
clinical trials. In our study, we hypothesized that bevaci-
zumab affects the antitumor activity of erlotinib and the 
available concentration of erlotinib in vivo depending on 
the levels of VEGF expression in NSCLC cells. We exam-
ined the relationship between the efficacy of bevacizumab 
and the levels of VEGF protein in NSCLC cells. Then we 
investigated antitumor activity of erlotinib plus bevaci-
zumab in erlotinib-resistant NSCLC xenograft models and 
evaluated the levels of erlotinib in tumor tissues.
Materials and methods
Cell cultures and reagents
The human NSCLC cell lines PC9, 11–18, H1975, H157, 
H460, A549 and the normal human bronchial epithelial cell 
line BEAS-2B were obtained from the American Type Cul-
ture Collection. Cells were cultured in RPMI 1640 medium 
(Gibco, Carlsbad, CA) or DMEM/F-12 medium (Gibco, 
Carlsbad, CA) supplemented with 10 % fetal bovine serum 
and 1 % penicillin–streptomycin at 37 °C in 5 % carbon 
dioxide. Bevacizumab and erlotinib were provided by Chu-
gai Pharmaceutical Co. Ltd (Tokyo, Japan) and Cayman 
Chemical (Ann Arbor, MI), respectively.
Cell growth assay
Six NSCLC cell lines were seeded (~2,000–5,000 cells 
per well, depending on cell type) onto 96-well plates. 
After 24 h of incubation, cells were treated with erlotinib 
(0–20 µmol/L), bevacizumab (0–20 ng/mL) or a combi-
nation of these agents (erlotinib 1 µmol/L; bevacizumab 
10 ng/mL) for 72 h in serum-containing medium. The via-
bility was determined by MTS assay (Promega, Madison, 
WI) according to the manufacturer’s instructions.
Human VEGF ELISA assay
The methods of VEGF quantification have been described 
previously [18, 19]. Briefly, the supernatant of cell culture 
media and homogenized tumor samples were collected for 
the assays. The human VEGF protein was determined with 
Quantikine ELISA kit (R&D Systems, Minneapolis, MN), 
according to the manufacturer’s instructions. Total protein 
levels were quantified by BCA assay (Thermo Scientific, 
Rockford, IL).
Xenograft models
Female BALB/cAJcI-nu/nu mice (5- to 6-week old) were 
obtained from CLEA Japan, Inc (Tokyo, Japan). Mice were 
kept in a 12-h light and dark cycle, and acclimatized for 
1 week before the study. The experimental protocols were 
reviewed and approved by the Kyushu University Animal 
Care and Use Committee (Fukuoka, Japan). “Principles 
of laboratory animal care” (NIH publication No. 85-23, 
revised 1985) were followed or comply with standards 
equivalent to the UKCCCR guidelines for the welfare of 
animals in experimental neoplasia [20].
Human NSCLC cells (5–10 × 106 H157, H460 or 
A4549 cells/mouse) were injected subcutaneously into the 
mice. When established tumors became palpable (~100–
300 mm3), mice were randomized into control and treat-
ment groups and treated with vehicle, bevacizumab (5 mg/
kg/twice weekly, i.p.), erlotinib (100 mg/kg/day, gavage) 
or erlotinib plus bevacizumab for the indicated periods. 
Moribund animals were killed to reduce suffering. Tumor 
volume and body weight were measured twice weekly. 
Tumor volume equation is V = ab2/2, where a and b are 
tumor length and width, respectively. Tumor growth inhibi-
tion (TGI,  %) formula is (TuGcontrol−TuGtest)/TuGcont
rol × 100 %, where TuG = final tumor size-pretreatment 
tumor size.
Determination of intratumoral erlotinib concentration 
by HPLC
Erlotinib levels in homogenized tumor tissues were deter-
mined by reverse-phase high-performance liquid chro-
matography (HPLC) with UV detection at 345 nm. 
Separation was achieved on a Waters Symmetry C18 
column (150 × 4.6 mm, 5.0 μm; Waters, Milford, MA) 
preceded by the use of a Symmetry C18 Guard column 
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(3.9 × 20 mm). The mobile phase was 50 mM potassium 
phosphate buffer (pH 4.8) containing 0.2 % triethylamine 
and acetonitrile (60:40, v/v), with 1.0 mL/min flow rate at 
25 °C. Sample pretreatment involved mixing 500 μL of 
tumor tissue homogenate with 80 μL of internal standard 
(70 μg/mL of midazolam in methanol) and 5 mL of tert-
butyl methyl ether for 10 min. After centrifugation (650 g, 
10 min, 4 °C), the organic top layer was transferred to a 
clean tube and dried under nitrogen gas at 37 °C. The resi-
due was dissolved in 250 μL of mobile phase. The solution 
was centrifuged (4,000 g, 30 min) and the supernatant was 
passed through a microporous membrane filter (Millex-GV 
0.22-μm filters, Millipore Corp., Bedford, MA). Insoluble 
materials were removed by filtration, and the filtrate was 
analyzed by high-performance liquid chromatography. The 
calibration curves were linear over a concentration range of 
20–4,000 ng/mL (r2 > 0.998).
Statistical analysis
Quantitative data are presented as the mean ± SEM. The 
Student’s t test and/or Mann–Whitney U test were used 
for comparison of two groups and one-way analysis of 
variance (ANOVA) test was for more than three groups. 
P < 0.05 was considered statistically significant. All data 
were representative of three independent experiments.
Results
Effects of erlotinib/bevacizumab on NSCLC cell lines 
in vitro
We examined the sensitivity of various NSCLC cells to 
erlotinib in vitro (Fig. 1a). The PC9 (EGFR exon 19 dele-
tion) and 11–18 (EGFR L858) cells were sensitive to 
erlotinib, with IC50 values of 0.043 ± 0.025 µmol/L and 
0.067 ± 0.0065 µmol/L, respectively (Fig. 1b). The H1975 
cell (L858R + T790 M) and the EGFR wild-type cells 
(H157, H460 and A549) were resistant to erlotinib, with 
IC50 values of 9.07 ± 2.11, 20.73 ± 4.66, 4.58 ± 2.08, and 
7.27 ± 0.69 µmol/L, respectively (Fig. 1b). The differences 
in sensitivity to erlotinib between the sensitive and the 
resistant cells were significant (P < 0.05).
Fig. 1  Effects of erlotinib/bevacizumab on NSCLC cell lines in vitro. 
MTS assay was used to evaluate the effects of erlotinib (a), bevaci-
zumab (c), and combination of erlotinib and bevacizumab (d) on the 
growth of NSCLC cell lines, which included cell lines with EGFR 
mutations: PC9 (EGFR exon 19 deletion), 11–18 (EGFR L858), 
H1975 (EGFR L858R and T790 M mutations) and EGFR wild-type 
cell lines: H157, H460 and A549. Cells were treated with erlotinib 
(0–20 µmol/L), bevacizumab (0–20 ng/mL) or combination of these 
agents (ER 1 µmol/L; BEV 10 ng/mL) for 72 h. The percentage of 
viable cells is shown relative to that of the untreated control. b The 
IC50 of erlotinib in the different cell lines. d No significant differ-
ences were noted between erlotinib alone and combination treatment 
in vitro (P > 0.05). Results are presented as the mean ± SEM. ER 
erlotinib, BEV bevacizumab
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Next, we applied bevacizumab alone or plus erlotinib 
to the NSCLC cells in vitro. As reported previously [21], 
bevacizumab alone did not inhibit the growth of the tested 
NSCLC cells in vitro (Fig. 1c). Growth inhibition with bev-
acizumab (10 ng/mL) plus erlotinib (1 µmol/L) was similar 
to that with erlotinib alone (1 µmol/L; Fig. 1d) in the six 
NSCLC cells (P > 0.05).
Human VEGF protein expression in NSCLC cell lines
As shown in Fig. 2, VEGF protein expression varied among 
the cells. In the erlotinib-resistant NSCLC cells, A549 cells 
secreted the lowest level of VEGF protein into the culture 
medium, H1975 and H460 cells expressed moderate lev-
els, and H157 cells secreted the highest level. The levels 
of VEGF protein in erlotinib-sensitive NSCLC cells PC9 
and 11–18 cells were lower than those secreted by H1975, 
H460 and H157 cells. Statistical analysis showed signifi-
cant differences between the NSCLC cells (except A549) 
and the control cell BEAS-2B (P < 0.05).
Effects of bevacizumab monotherapy in NSCLC xenograft 
models
According to the results in vitro, EGFR wild-type cells 
H157, H460 and A549 are erlotinib-resistant cells that 
express high, moderate and low levels of VEGF pro-
tein, respectively. We assessed the effect of bevacizumab 
monotherapy in these three xenograft models. Bevaci-
zumab (5 mg/kg) was well tolerated with no significant 
effects on body weight (Supplementary Fig. 1) [22] and 
showed significant antitumor activity in the H157 and 
H460 models (P < 0.01; Fig. 3a, b) rather than in the A549 
model (Fig. 3c). TGI  % were 80.82, 65.62 and 57.14 % 
in H157, H460 and A549 models at the end of treatment, 
respectively (Fig. 3d). These results suggested the NSCLC 
xenograft model that expressed high levels of VEGF pro-
tein was more sensitive to VEGF blockade than the models 
with lower VEGF protein.
We also examined the levels of human VEGF protein in 
tumor tissues. Consistent with the previous observations in 
vitro, the level of VEGF protein in the H157 tumor tissue 
was highest, followed in order by H460 and A549 tumor 
tissues (P < 0.01; Fig. 3e). Bevacizumab significantly 
reduced the level of VEGF protein in tumor tissues from 
the H157 (P < 0.05) and H460 (P < 0.001) models but not 
in that from the A549 model (P > 0.05). This result was due 
to the function of bevacizumab that neutralizes VEGF [23, 
24]. The changes in VEGF levels observed between the 
bevacizumab and control groups also reflected the sensitiv-
ity of NSCLC xenografts to bevacizumab treatment.
Antitumor activity of erlotinib combined with bevacizumab 
in NSCLC xenograft models
Current chemotherapy/targeted regimens have used multi-
ple agents for the treatment of carcinomas to improve effi-
cacy and avoid the development of resistance [8, 25, 26]. 
Because the effect of combined agents to erlotinib is dif-
ficult to detect in erlotinib-sensitive tumor, we investigated 
the efficacy of erlotinib plus bevacizumab in erlotinib-
resistant xenografts in a separate experiment.
Erlotinib alone did not cause significant inhibition 
of tumor growth compared with vehicle in the H157 
model (TGI < 40 %; Fig. 4a, d) or in the H460 model 
(TGI < 30 %; Fig. 4b, e). Erlotinib plus bevacizumab 
achieved significant tumor inhibition compared with treat-
ment with erlotinib alone (P < 0.05) or vehicle (P < 0.001) 
in the H157 model (TGI > 85 %; Fig. 4d and Supplemen-
tary Fig. 2a). In contrast, combination treatment inhibited 
H460 tumor growth by about 40 % by the end of study 
(Fig. 4e), but the inhibition was not significantly greater 
than that of erlotinib alone or vehicle (Fig. 4b and Sup-
plementary Fig. 2b). Although A549 cells were resistant 
to erlotinib in vitro, A549 tumor growth in nude mice was 
moderately suppressed by erlotinib (TGI > 52 %; Fig. 4c, 
f). Blockade by combined treatment inhibited A549 tumor 
growth more than treatment with vehicle (P < 0.01), but 
was not more effective than treatment with either agent 
alone (Fig. 4c and Supplementary Fig. 2c).) No substantial 
weight loss was observed during treatment (Supplementary 
Fig. 2  Levels of human VEGF protein in NSCLC cell lines. Human 
VEGF protein in culture medium (2 mL with free fetal bovine serum) 
of NSCLC cell lines (3 × 105 cells) and the human bronchial epi-
thelial cell line BEAS-2B (control) was assessed by ELISA. Data are 
presented as the mean ± SEM. *P < 0.05 for cells compared with 
BEAS-2B; #P < 0.05 for cells compared with H157
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Fig. 3). Taken together, these results indicated that erlotinib 
plus bevacizumab was capable of inhibiting tumor growth 
and/or partially reversing resistance to erlotinib in estab-
lished xenografts with high VEGF expression.
Concentration of erlotinib in tumor tissues of xenograft 
models
Previous studies have shown that bevacizumab can enhance 
drug delivery to tumors [15]; however, this remains con-
troversial [16, 17]. According to a previous study [27], 
the erlotinib concentration in mouse tumors reaches its 
peak concentration within 1 h after p.o. administration and 
declines rapidly for the next 6 h. Therefore, we excised 
tumor samples in athymic mice 1 h after administrating 
erlotinib p.o. on the last day of treatment and observed the 
changes in intratumoral erlotinib concentration.
Erlotinib concentrations in the H157, H460 and 
A549 tumor tissues treated with erlotinib alone 
or plus bevacizumab reached 3.98 ± 0.65 and 
7.61 ± 1.28 µg/g (P = 0.289; Fig. 5a); 3.15 ± 0.094 and 
4.11 ± 0.17 µg/g (P = 0.0751; Fig. 5b); 13.19 ± 2.39 and 
10.00 ± 0/0.30 µg/g (P = 0.569; Fig. 5c), respectively. The 
changes in intratumoral erlotinib concentration were con-
sistent with the antitumor activity of erlotinib plus bevaci-
zumab treatment in these three xenografts. Compared with 
an increased erlotinib concentration following combination 
treatment in H157 tumor tissue, A549 tumors showed the 
opposite results.
Discussion
Erlotinib monotherapy is approved for treatment of patients 
with advanced or metastatic NSCLC, while bevacizumab 
monotherapy is not standard for NSCLC treatment [5, 7]. 
The objective of our study was to determine whether there 
were conditions under which the addition of bevacizumab 
would enhance antitumor activity of erlotinib against 
NSCLC tumors in vitro and in vivo. First, we found that 
Fig. 3  Effects of bevacizumab monotherapy on NSCLC xenograft 
models with primary resistance to erlotinib. a, b and c Tumor vol-
ume over time in response to bevacizumab (5 mg/kg; n = 4–7). The 
Mann–Whitney U test was used to compare tumor volume at the last 
measurement between the groups (ΔT/ΔC): **P < 0.01 in H157 
tumors (a) and H460 tumors (b); nsP > 0.05 in A549 tumors (c). d 
TGI  % in each model was calculated from the beginning of beva-
cizumab treatment. e The levels of human VEGF protein in tumor 
tissues of H157, H460 and A549 models were assayed by ELISA. 
The Student’s t test was used to compare bevacizumab and vehicle 
treatment in each model: *P < 0.05, ***P < 0.001, nsP > 0.05. For 
comparison between the three xenograft tumors, one-way ANOVA 
was used: ϕϕP < 0.01, ϕϕϕP < 0.001. Data are expressed as the 
mean ± SEM. ER erlotinib, BEV bevacizumab
1302 Cancer Chemother Pharmacol (2014) 74:1297–1305
1 3
Fig. 4  Effects of erlotinib plus bevacizumab on tumor growth in 
NSCLC xenograft models. a, b and c Changes in tumor volume over 
time in response to treatment with vehicle, bevacizumab (5 mg/kg), 
erlotinib (100 mg/kg) or combination of bevacizumab (5 mg/kg) and 
erlotinib (100 mg/kg) for 2 weeks (n = 3–7). One-way ANOVA was 
used to compare tumor volume at the last measurement between the 
treatment groups in each xenograft model: H157 model (a), H460 
model (b), and A549 model (c). ***P < 0.001, *P < 0.05, **P < 0.01 
for combination treatment or bevacizumab treatment compared with 
the vehicle (ΔT/ΔC); ϕP < 0.05 for combination treatment compared 
with erlotinib alone (ΔT/ΔT′); and nsP > 0.05 means no significant 
differences. d, e and f TGI  % by erlotinib, bevacizumab and combi-
nation treatment in three models. g, h and i Images of tumor samples 
in three xenografts. Data are expressed as the mean ± SEM. ER erlo-
tinib, BEV bevacizumab
Fig. 5  Erlotinib concentration in tumor tissues. HPLC was used to 
determine the erlotinib concentration in the tumor tissues from the 
xenograft models treated with erlotinib alone or combined with bev-
acizumab. Data are expressed as the mean ± SEM. The Student’s t 
test was used to compare erlotinib and combination groups in each 
model: P = 0.289 (a H157 model), P = 0.0751 (b H460 model) and 
P = 0.569 (c A549 model). ER erlotinib, BEV bevacizumab
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erlotinib plus bevacizumab were no extra inhibitory than 
erlotinib alone in vitro. This result is consistent with those 
of a previous study [21] and may be explained by the fact 
that VEGFR is expressed on vascular endothelium but not 
on malignant cells in human solid tumor types (including 
lung cancer) [28]. Because the change of erlotinib concen-
tration is undetectable in erlotinib-sensitive tumor due to 
effective apoptosis induction to the cancer cells with low 
level of erlotinib, we then produced xenograft models bear-
ing primarily erlotinib-resistant NSCLC cells to investigate 
the erlotinib accumulation in the tumor with bevacizumab 
combination. We found that the tumors expressing higher 
levels of VEGF protein were more responsive to inhibi-
tion by bevacizumab and combination treatment. These 
results suggest that the effect of dual inhibition of EGFR 
and VEGF is dependent on VEGF expression in EGFR 
TKI-resistant xenografts. Finally, we demonstrated a trend 
toward increasing concentrations of erlotinib in the tumor 
tissues during treatment with erlotinib and bevacizumab 
compared with erlotinib alone. This effect also appeared to 
be influenced by the levels of VEGF protein.
VEGF plays a central role in angiogenesis and is nec-
essary for endothelial cell survival in tumors, while the 
expression of VEGF protein depends on the type of cancer 
[29]. Decreasing VEGF levels by bevacizumab is known 
to block angiogenesis, transiently normalize tumor ves-
sels, sensitize tumors to radiotherapy and chemotherapy, 
improve tumor oxygenation and decrease interstitial fluid 
pressure, as well as restore delivery of drugs into the tumor 
[15, 30]. These might explain why the combination treat-
ment worked better in the H157 model with high VEGF 
expression. In addition, because EGFR plays a vital role 
in the regulation of cell proliferation, survival and differ-
entiation [31], partial normalization of tumor vessels by 
bevacizumab could cause proliferation of the tumor cells, 
which could make them more sensitive to EGFR TKI. As 
reported previously, EGFR TKI is known to be dose-related 
inhibition of EGFR function [27, 32, 33]. Therefore, beva-
cizumab combined with erlotinib is reasonable to enhance 
the antitumor effect by increasing intratumoral concentra-
tion of erlotinib.
On the other hand, the differences in efficacy for com-
binations of erlotinib plus bevacizumab between our study 
and the clinical trials [12, 13] are just like previous reports, 
that clinical efficacy is lower than that observed in preclini-
cal cancer models [15, 16, 31, 34]. One possible explana-
tion is that the efficacy of bevacizumab alone or combined 
with other agents differs among tumor types, such as trans-
plantable tumors in mice, spontaneous tumors and tumors 
from patients, which exhibit different degrees of vessel 
abnormality and levels of VEGF protein [15]. An alter-
nate explanation for the variability in treatment efficacy 
is that vessel normalization by VEGF blockade is limited 
to a small window in treatment time. The window of nor-
malization in murine models is relatively short and occurs 
soon after administration of bevacizumab compared with 
that in humans [29], which may explain several paradoxi-
cal findings reported recently and suggest that the schedule 
and dosing of combination therapies warrant considerable 
attention. For example, bevacizumab and cetuximab (anti-
EGFR monoclonal antibody) have shown promising results 
in clinical trials in NSCLC [35]. However, this is at odds 
with the results of a study which showed that bevacizumab 
reduced tumor uptake of cetuximab in SUM149 xenografts 
(a breast cancer xenograft) [16]. A bevacizumab/docetaxel 
combination was more effective than docetaxel alone in 
reducing breast and prostate cancer cell growth [36], but a 
rapid decrease in the delivery of docetaxel to tumors after 
bevacizumab therapy was observed in another study [17]. 
Notably, although the erlotinib concentration in the com-
bination group of H157 model with high VEGF levels was 
much higher than that in the erlotinib only group, no signifi-
cant difference in intratumoral erlotinib concentration was 
observed between these two groups in any of the three mod-
els. This might be attributed to different blood flow even 
within the same tumor, because abnormal vessels in tumors 
result in continuous vessel remodeling, as well as facilitate 
drug distribution in perfused and leaking vessels [16, 17].
Until now, it is controversial whether EGFR TKIs alone 
or combined with other agents are recommended to patients 
with EGFR wild-type NSCLC as a second- or third-line 
treatment [37–42]. Lung cancer is not homogenous, and 
any change in histology or mutational status could happen 
after chemotherapy and/or targeted therapy, which suggests 
that EGFR wild-type should not be invalid indication for 
EGFR TKI. Although cytotoxic chemotherapy remains the 
backbone of therapy for patients with advanced NSCLC, 
EGFR TKIs and VEGF inhibitors are potential ones. There-
fore, further understanding of mechanisms and modes in 
dual inhibition of EGFR and VEGF is a priority. As there 
are inconsistent reports on VEGF blockade affecting the 
delivery of combined drugs, the precise effects of these 
reactions should be further investigated.
In conclusion, we demonstrated that bevacizumab may 
be useful for enhancing antitumor activity of erlotinib by 
increasing the intratumoral concentration of erlotinib in 
some tumors that express high levels of VEGF protein. 
Our study is limited by the small number of tissue samples 
evaluated and not assessing other angiogenic factors (such 
as basic FGF or PDGF [38] ) that tumor may depend on. 
Besides, to establish histologically and genetically accurate 
models of human cancer, genetically engineered model will 
be used for further study. Overall, it is important to under-
stand the principles and mechanisms of the combination 
approach for effectively translating preclinical studies into 
clinical practice for better efficacy.
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